

*B2 removed*  
transcriptional start site of the CEA gene and a CEA enhancer.

---

*B3*  
38. (amended) A composition comprising the adenovirus vector of claim 33, and a pharmaceutically acceptable excipient.

---

39. A host cell transformed with the adenovirus vector of claim 33.

---

40 (new) The adenovirus vector of Claim 33, wherein said adenovirus gene essential for replication is an early gene.

---

*B4*  
41. (new) The adenovirus vector of Claim 40, wherein said early gene is selected from the group consisting of E1A, E1B and E4.

---

42. (new) The adenovirus vector of Claim 33, wherein said first and said second adenovirus gene essential for replication are E1A and E1B.

---

43. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence from about -6.1 to about -3.8 relative to the transcriptional start site of the CEA gene.

---

44. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence from about -14.5 to about -3.8 relative to the transcriptional start site of the CEA gene.

---

45. (new) The adenovirus vector of Claim 36 wherein said CEA promoter comprises the nucleotide sequence as shown in SEQ ID NO:1.

---

46. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence within the region from about -13.6 to about -10.6 relative to the transcriptional start site of the CEA gene.

---

47. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises the nucleotide sequence from about -14.5 to about -10.6 relative to the transcriptional start site of the CEA gene.

---